Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontier 2: Mim8 prophylaxis in haemophilia A with or without inhibitors
jRCT2031210643Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of denecimig in hemophilia A (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treated bleeds from randomisation (week 0) to end of main period (week 26). Started Feb 2022; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2031210643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210643.